RxDoctor Payments Data

David Friedman, MD

Procedural Dermatology · Anaheim, CANPI 1629141866

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations.

$2,964in general payments, 2019–2025

Across 136 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$634
  • AbbVie$564
  • Novartis$355
  • Johnson & Johnson$239
  • Dermavant Sciences, Inc.$220
  • Lilly USA, LLC$179
  • plus $774 from 12 others

What the payments were for

  • Food & beverage$2,964100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,964 in reported general payments places this provider in the 55th percentile of 108 procedural dermatology providers in California.

See all procedural dermatology providers in California

Medicare billing

Part B allowed, 2024
$206,314
Medicare patients
396
Services billed
5,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Unoready PenSecukinumab19$206,216
OtezlaApremilast15$72,845
Calcipotriene25$5,718
Fluocinonide116$5,018
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc220$4,095
Tacrolimus35$3,972
Metronidazole83$3,347
Triamcinolone Acetonide329$3,096
Ketoconazole281$3,068
Doxycycline Hyclate152$2,635
CiclopiroxCiclopirox Olamine110$1,926
Mometasone Furoate71$1,202
Fluorouracil18$1,150
Alclometasone Dipropionate18$1,116
Clobetasol Propionate39$923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$634$72,84515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 108 procedural dermatology providers in California.

Other procedural dermatology in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →